Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has made significant progress in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, with accelerated patient screening and enrollment across multiple sites in the US and Australia. The company also achieved a successful regulatory meeting with the FDA regarding major depressive disorder, marking a major accomplishment that could enhance future partnerships and funding opportunities. Additionally, the World Health Organization granted a unique name to Xanamem, recognizing its novel mechanism of action, and the company continues to advance its manufacturing and strategic planning efforts.
More about Actinogen Medical
Actinogen Medical is a biotechnology company focused on developing treatments for central nervous system diseases. Their primary product is Xanamem, an orally administered drug designed to control toxic cortisol levels in the brain, targeting conditions such as Alzheimer’s disease and major depressive disorder.
YTD Price Performance: 25.00%
Average Trading Volume: 75,000
Technical Sentiment Signal: Sell
Current Market Cap: $55.14M
For an in-depth examination of ACW stock, go to TipRanks’ Stock Analysis page.